Foralumab
As of the edition of 20 October 2026, Foralumab is an antibody: in active development; acts on CD3D, CD3E and CD3G.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 10, 4 stopped early
- Disease areas
- Nervous system; Digestive system; Immune system; Nutrition and metabolism; Hormones; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 7 | 2 | 3 | 2 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Light Chain Bioscience - | Lead sponsor of trials | 2006 to now |
| Tiziana Life Sciences | Lead sponsor of trials | 2017 to now |